FDA Approves Lumipulse Blood Test to Help Diagnose Alzheimer’s
The U.S. Food and Drug Administration (FDA) has approved the Lumipulse blood test, marking the first time a blood test can be used to help diagnose Alzheimer's disease, offering a more accessible and less invasive diagnostic option compared to traditional…
Lafayette, IN, October 16, 2026 —
The U.S. Food and Drug Administration has approved the Lumipulse blood test for use in helping diagnose Alzheimer’s disease. The approval marks the first time a blood test can be used for that purpose, according to the information provided.
The test is described as a more accessible and less invasive diagnostic option than traditional methods such as PET scans and spinal taps. The available information does not explain how the test works, what results it measures, or how clinicians are expected to use it alongside other diagnostic tools.
The approval establishes a new blood-test option in the diagnostic process, but the details provided do not specify which patients are eligible, where the test will be available, or when it may be offered. They also do not state whether the test is intended to be used on its own or in combination with other assessments.
No information was provided about the evidence reviewed by the FDA, the test’s accuracy, its cost, or the timing of its availability. Those details are not included here, and the approval should not be taken to mean that the test alone confirms a diagnosis. The information provided describes its role as helping to diagnose Alzheimer’s disease.
The approval distinguishes Lumipulse as the first blood test identified in the summary for this diagnostic use. Further details about how the option may fit into clinical practice were not provided.
Story summarized from the original created by Heather Graf on www.wlfi.com, see more information here.
Media gallery
